Antibiotics Market To Gain Demand Quickly Due To Rising Prevalence Of Infectious Diseases Till 2024: Grand View Research, Inc.
The antibiotics market is expected to reach USD 57.0
billion by 2024, according to the new report by Grand View Research, Inc.
Rising prevalence of infectious diseases especially in developing regions such
as Asia Pacific and MEA is anticipated to contribute towards market growth.
More than 15.0% of the deaths, in
children below the age of five, are estimated to be due to pneumonia and
according to the statistics provided by the WHO about 9.2 million deaths were
recorded in 2015. Similar to tuberculosis, the highest prevalence of the
disease is identified to be in the South Asian and Sub-Saharan regions.
Currently, the required antibiotic treatment is available only to one third of
the infected population, thereby increasing the disease burden.
Government reforms specific to
antibiotics such as the Generating Antibiotics Incentives Now (GAIN) Act in the
U.S. are projected to help market growth over the forecast period. This further
expected facilitate development of advanced drugs.
On the contrary, uncertain
regulatory policies are likely to hinder the growth of this vertical impacting
market growth significantly. In 2013, the U.S. FDA revised the guidance for
registration trials for drugs used in the treatment of acute bacterial skin and
skin structure infections. The guidance states the use of short term measures
of anti-infective efficacy (percent reduction in lesion size at 48 to 72 hours)
as opposed to long term measures such as resolution of infection at 10-14 days,
which is termed as Test to Cure or TOC.
Browse full research report on Antibiotics Market: http://www.grandviewresearch.com/industry-analysis/antibiotic-market
Further Key Findings From
the Study Suggest:
- Antibiotic segment including tetracyclines,
imidazoles, lincosamides and monoclonal antibodies held commanding share
in 2015 and are also anticipated to grow at a lucrative growth rate over
the forecast period
- Development of monoclonal antibodies for antibiotic
resistant microorganism is key highlight of this segment. Increasing
incidences of pneumonia, blood stream infections, and urinary tract
infections (UTI) are anticipated to foster the usage of carbapenems class
of antibiotics.
- Cell wall synthesis inhibitors dominated the
mechanism outlook in 2015. Majority of the antibiotics such as
penicillins, cephalosporins and carbapenems forms the cell wall synthesis
inhibitor class.
- RNA synthesis inhibitors as well as folic acid
synthesis inhibitors are anticipated to witness healthy growth over the
forecast period. Development of several antiviral drugs which inhibit
transcription and reverse transcription process are anticipated to support
the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as
they have wide application scope.
- Asia Pacific on account of huge population base, high
prevalence of infectious diseases, regulation reforms and greater usage of
generic medicine held commanding share in 2015.
- Latin America, especially Brazil with strong growth
in pharmaceutical sector is also projected to exhibit remunerative growth.
Outbreak of certain viruses such as Ebola in African region also
contributed towards the significant growth of MEA region.
- Some of the key players in this vertical are Pfizer,
Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi,
Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company
and Astellas Pharma, Inc.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antibiotics market on
the basis of drug class and region:
Global Antibiotics Drug Class Outlook (Revenue, USD
Million, 2013 - 2024)
- Cephalosporins
- Penicillins
- Fluoroquinolones
- Macrolides
- Carbapenems
- Aminoglycosides
- Sulfonamides
- Other
Global Mechanism Outlook (Revenue, USD Million, 2013 -
2024)
- Cell
Wall Synthesis Inhibitors
- Protein
Synthesis Inhibitors
- DNA
Synthesis Inhibitors
- RNA
Synthesis Inhibitors
- Mycolic
Acid Inhibitors
Antibiotics Regional Outlook (Revenue, USD Million, 2013
- 2024)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment